McDavid Stilwell - Coherus BioSciences Chief Officer
| CHRS Stock | USD 1.03 0.08 8.42% |
Insider
McDavid Stilwell is Chief Officer of Coherus BioSciences
| Age | 52 |
| Address | 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 649 3530 |
| Web | https://www.coherus.com |
McDavid Stilwell Latest Insider Activity
Tracking and analyzing the buying and selling activities of McDavid Stilwell against Coherus BioSciences stock is an integral part of due diligence when investing in Coherus BioSciences. McDavid Stilwell insider activity provides valuable insight into whether Coherus BioSciences is net buyers or sellers over its current business cycle. Note, Coherus BioSciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Coherus BioSciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
McDavid Stilwell over six months ago Disposition of 3457 shares by McDavid Stilwell of Coherus BioSciences at 6.84 subject to Rule 16b-3 |
Coherus BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.1094) % which means that it has lost $0.1094 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Coherus BioSciences' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.07 in 2025, whereas Return On Capital Employed is likely to drop (0.71) in 2025. At this time, Coherus BioSciences' Other Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 56.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 56.5 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ted Jenkins | Spero Therapeutics | N/A | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Daniel Welch | Nuvation Bio | 63 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Nicole White | Assembly Biosciences | N/A | |
| MBA BS | CytomX Therapeutics | 46 | |
| Michelle Doig | Nuvation Bio | 46 | |
| David MD | Nuvation Bio | 55 | |
| Lieping MD | NextCure | 67 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| James Brady | Spero Therapeutics | N/A | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Gary Hattersley | Nuvation Bio | 58 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| MBA MD | Spero Therapeutics | 44 | |
| Uri MD | Assembly Biosciences | 53 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Sumita JD | Instil Bio | 50 | |
| Michael MSBA | NextCure | 64 | |
Management Performance
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.11 |
Coherus BioSciences Leadership Team
Elected by the shareholders, the Coherus BioSciences' board of directors comprises two types of representatives: Coherus BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coherus. The board's role is to monitor Coherus BioSciences' management team and ensure that shareholders' interests are well served. Coherus BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coherus BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladimir Vexler, Chief Scientific Officer | ||
| Bryan Mcmichael, Principal Accounting | ||
| Dennis Lanfear, Chairman, CEO and Pres | ||
| Michael Chen, Senior Trade | ||
| Theresa Lavallee, Chief Board | ||
| MRCP MD, Chief Officer | ||
| Rebecca Sunshine, Chief Officer | ||
| Scott Saywell, Executive Development | ||
| Jodi Sievers, Vice Communications | ||
| Karen Kotz, Ex Accounts | ||
| Jami Taylor, Vice Relations | ||
| Christopher Slavinsky, Chief Officer | ||
| Cheston Turbyfill, Vice Communications | ||
| Andy Rittenberg, Executive Counsel | ||
| McDavid Stilwell, Chief Officer | ||
| Paul Reider, Chief Officer | ||
| Richard Hameister, Chief Officer |
Coherus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coherus BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | (0.66) % | ||||
| Current Valuation | 262.71 M | ||||
| Shares Outstanding | 115.9 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 57.56 % | ||||
| Number Of Shares Shorted | 31.81 M | ||||
| Price To Earning | 4.22 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.